Ronald Luna, MD
Internal Medicine · Seaford, DENPI 1285982447
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 193 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations.
Across 193 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$591
- AbbVie$428
- AstraZeneca$333
- Pfizer$291
- Lilly USA, LLC$287
- Exact Sciences$174
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,47897%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 38 | $591 |
| AbbVie | 22 | $428 |
| AstraZeneca | 21 | $333 |
| Pfizer | 17 | $291 |
| Lilly USA, LLC | 15 | $287 |
| Exact Sciences | 8 | $174 |
| Amgen | 3 | $159 |
| Novartis | 8 | $157 |
| Astellas Pharma US Inc | 3 | $137 |
| Boehringer Ingelheim | 8 | $117 |
| Sunovion Pharmaceuticals Inc. | 5 | $89 |
| Dexcom, Inc. | 3 | $87 |
| Phathom Pharmaceuticals, Inc. | 5 | $80 |
| Johnson & Johnson | 6 | $79 |
| Otsuka America Pharmaceutical, Inc. | 4 | $73 |
| Bayer | 4 | $56 |
| Kowa Pharmaceuticals America, Inc. | 3 | $55 |
| Abbott | 3 | $53 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| Shield Therapeutics Inc | 1 | $25 |
| Boston Scientific | 1 | $24 |
| Smith+Nephew | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Corcept Therapeutics | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| Merck | 1 | $19 |
| Evoke Pharma, Inc. | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
How this compares
$3,578 in reported general payments places this provider in the 85th percentile of 477 internal medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 14 | $190,728 |
| OzempicSemaglutide | 125 | $136,518 |
| EliquisApixaban | 201 | $105,390 |
| XareltoRivaroxaban | 92 | $71,639 |
| JardianceEmpagliflozin | 32 | $52,730 |
| RybelsusSemaglutide | 23 | $40,295 |
| JanuviaSitagliptin Phosphate | 18 | $30,145 |
| TrulicityDulaglutide | 31 | $23,563 |
| EntrestoSacubitril/Valsartan | 19 | $23,197 |
| FarxigaDapagliflozin Propanediol | 22 | $19,825 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $18,165 |
| MyrbetriqMirabegron | 28 | $14,347 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 34 | $12,507 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $10,874 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 78 | $8,733 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $591 | $176,813148 claims |
| PfizerEliquis | $291 | $105,390201 claims |
| Johnson & JohnsonXarelto | $79 | $71,63992 claims |
| Boehringer IngelheimJardiance | $117 | $52,73032 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere, Symbicort | $333 | $39,33265 claims |
| MerckJanuvia | $19 | $30,14518 claims |
| Lilly USA, LLCTrulicity | $287 | $23,56331 claims |
| NovartisEntresto | $157 | $23,19719 claims |
| Astellas Pharma US IncMyrbetriq | $137 | $14,34728 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $2,113194 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 477 internal medicine providers in Delaware.
Other internal medicine in Seaford
- Mark EvangelistaSeaford$11K
- Louis CrevecoeurSeaford$6K
- Purna SharmaSeaford$5K
- Yeswanth AttotiSeaford$5K
- Seth IvinsNewark$384K
- Beshara HelouGeorgetown$143K
- Tabassum SalamNewark$62K
- Fabricio AlarconGeorgetown$30K
- Jose CastroWilmington$27K
- Marcia Gina CastroWilmington$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.